Ambion, Inc.

Download Report

Transcript Ambion, Inc.

NAT Testing in Solid Tissues and Organs: A Pre-analytical Solution for Nucleic Acid Stabilization

Cindy WalkerPeach, Ph.D.

[email protected]

Copyright © 2007 Asuragen, Inc

Ambion Diagnostics Becomes Asuragen!

Ambion Research Products Division Purchased by Applied Biosystems Group (NYSE: ABI) for $273M March 2, 2006 Ambion, Inc.

Formed 1989 Ambion Diagnostics Division Formed 2000 Ambion Services Division Formed 2005 Asuragen, Inc.

Ambion Diagnostics Ambion Services Key Ambion R&D Scientists and Executive Team

Copyright © 2007 Asuragen, Inc

RNARetain

Pre-analytical Solution • Overview • Applications • Examples • Conclusions

Copyright © 2007 Asuragen, Inc

RNARetain Overview

• Versatile, non-toxic, non-organic solution for preservation of nucleic acids by inactivating nucleases to prevent degradation of RNA/DNA • Stabilizes nucleic acids at room temperature, without requirement of dry ice or liquid nitrogen, thereby allowing biological samples to be shipped on wet ice or at ambient temperatures • Compatible with all downstream RNA extraction methods • Based on formulation widely used in life science research (RNA

later

- Ambion, Inc.) • Covered by US patent: 6,204,375 and WW equivalents Copyright © 2007 Asuragen, Inc

RNARetain - cGMP Traceability

• Manufactured under QSR 21 CFR Part 820 guidelines to ensure lot-to-lot consistency critical for reagents used in clinical specimen collection and storage for downstream RNA extraction and molecular analysis • Compatibility with major extraction procedures and molecular analysis techniques will allow end-user to qualify reagent for use in specific downstream applications • cGMP traceability provides consistent performance in end user’s hands Copyright © 2007 Asuragen, Inc

Selected Publications

• Development and validation of a method for using breast core needle biopsies for gene expression microrarray analyses Matthew Ellis,

et al

.

Clin Cancer Res. 2002, 8:1155-1166

• The effect of sample degradation and RNA stabilization on classical swine fever virus RT-PCR and ELISA methods Stuart D. Blacksell, Syseng Khounsy and Harvey A. Westbury.

J. Vir Methods. 2004, 118(1):33-37

• Viral infectivity is maintained by an RNA protection buffer C. Uhlenhaut and M. Kracht.

J. Virol Methods. 2005, 128(1-2):189-91

• Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative Dondapati Chowdary,

et al

.

JMD. 2006, Vol. 8, No. 1

• Currently there are over 1,000 citations since Jan 2001 in HighWire Press: http://Highwire.Stanford.edu

Copyright © 2007 Asuragen, Inc

Unmet Clinical Need…………

Easy and Safe Sample Acquisition “Freezes” mRNA and microRNA Expression Profiles Long-Term Cell/ Tissue Banking

Clinical

Virus Preservation Molecular Isolation (RNA/DNA) Convenient Sample Transport

Clinical Research, Tissue/Cell Banking, Expression Profiling Services, Molecular Diagnostics

Copyright © 2007 Asuragen, Inc

Intracellular RNA Preservation

5E+5 MCF-7 Breast Tissue Cells

Sample RNARetain 260/280 28S:18S

2.02

1.75

RIN

10.00

Flash Frozen RNARetain Flash Frozen

2.01

1.72

1.87

1.20

1.30

1.45

9.65

9.15

8.90

Flash Freeze RNARetain

Flash Freeze Or RNARetain x4

mir

Vana ™ or Trizol ® Extraction Nanodrop ® Agilent Bioanalyzer Copyright © 2007 Asuragen, Inc

RNARetain preserves the quality of intracellular RNA to the same extent as the currently established standard of flash-freezing

qRT-PCR Reproducibility

5E+5 MCF-7 Cells In RNARetain 1E+3 HCV1b ARQ Process Control

mir

Vana Extraction HCV1b (process con) and TBP (internal con) qRT-PCR at 40ng sample input x3 x5

Sample # 260/280 28S:18S RIN 1

1.96

1.73

9.87

2 3

1.99

2.09

1.83

1.77

9.97

9.90

4 5

1.98

1.97

1.63

1.77

9.90

9.93

40 45 35 30 25 20 43 41 39 37 35 33 31 29 27 15 25 1 2 3 4 5

Sample Number Reproducible RNA quality and qRT-PCR amplification efficiency is achieved for intracellular RNA extracted from RNARetain preserved cells

Copyright © 2007 Asuragen, Inc TBP ARQ HCV1b

Armored RNA

®

Recovery from RNARetain

1E+7 HCV1b ARQ + or - RNARetain RNA Isolation (Trizol or

mir

Vana Kit) HCV1b qRT-PCR x3 x3 40 35 30 25 20 15

+ + RNARetain

mir

Vana Trizol Process Rep 1 Process Rep 2 Process Rep 3

Pseudo-viral particles can be preserved in and extracted from RNARetain in a reproducible manner

Copyright © 2007 Asuragen, Inc

RNARetain Data Summary

• Preserves quality of intracellular RNA to same extent as flash-freezing • Does not interfere with reproducibility of intracellular RNA extraction and analysis methods • Effective for storage and preservation of viral RNA as indicated by compatibility with Armored RNA Copyright © 2007 Asuragen, Inc

Case Study: C N n=7 Ch n=7 Combination of two microRNAs can be used to distinguish normal, chronic pancreatitis, and carcinoma samples Copyright © 2007 Asuragen, Inc

Analysis of FNA Specimens

Endoscopic microdissection of pancreatic mass (EU-FNA) Preservation in RNARetain RNA Isolation microRNA expression profiling (qRT-PCR)

Signal ratios for two miRNAs showing differential expression specific to cancerous (ca) or normal (N) tissue are maintained in RNARetain (FNA samples)

6 12 2 8 -2 4 -6 0 -10 -4 -14

Ca FNA

n=7

Ca N Frozen

n=2 n=2

RNARetain preserves miRNA signatures for downstream molecular profiling

-8

Ca Frozen N

n=10 n=7 Frozen tissues from Szafranska et al.

Copyright © 2007 Asuragen, Inc

Closing Remarks

• RNARetain is a pre-analytical solution which stabilizes intracellular RNA in cells and solid tissues for downstream extraction and molecular characterization • RNARetain is compatible with Armored RNA, illustrating potential utility in collection and storage of viral-infected tissues, thus eliminating the need for immediate processing or flash freezing • Next step will be to identify beta test sites to evaluate clinical utility of RNARetain for collection and transport of viral-infected tissue specimens • Agendia, B.V.

Used in conjunction with MammaPrint of breast cancer recurrence ® 70 gene expression signature which predicts the risk Received US FDA approval Feb 6, 2007 Copyright © 2007 Asuragen, Inc